PCG Advisory

08/25/2025

Insight Molecular Diagnostics $IMDX CFO Andrea James was featured on the Empowered Patient Podcast, discussing the company’s mission to democratize access to molecular diagnostics. The episode highlighted iMDx’s focus on transplant monitoring, its pathway toward FDA clearance, and global adoption of its RUO kit in research settings.
https://finance.yahoo.com/news/imdx-cfo-andrea-james-featured-131500754.html

08/25/2025

Coya Therapeutics Announces FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

Coya Therapeutics Announces FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

08/21/2025

Congratulations to Quoin Pharmaceuticals $QNRX as its NETHERTON NOW campaign surpasses 1M video views and 14M impressions, raising global awareness of Netherton Syndrome, a rare and devastating genetic skin disease.


https://finance.yahoo.com/news/quoin-pharmaceuticals-netherton-now-campaign-123000844.html

08/12/2025

Coya Therapeutics Reports Second Quarter Financial Results and Provides a Corporate Update
https://pcgadvisory.com/pcgnews/coya-therapeutics-reports-second-quarter-financial-results-and-provides-a-corporate-update/

08/12/2025

Quoin Pharmaceuticals has released the fourth episode of its Netherton Now series, featuring international patient advocate Mandy Aldwin-Easton. In the video, Mandy shares her lifelong challenges with Netherton Syndrome, from severe flare-ups and hospitalizations to the emotional toll of living with a rare, painful skin disorder. Her story underscores the urgent need for effective treatments, as Quoin continues advancing its lead candidate, QRX003, in multiple late-stage pivotal trials for Netherton Syndrome.

08/12/2025

IMDxInc $IMDX Reports Q2 2025 Results and Momentum Toward GraftAssureDx Launch

IMDX Reports Q2 2025 Results and Momentum Toward GraftAssureDx Launch

08/11/2025

SkyX Platforms Corp $SKYX To Host Q2 2025 Corporate Update Call On August 12

Investornewsbreaks SKYX Platforms Corp. (NASDAQ: SKYX) To Host Q2 2025 Corporate Update Call On August 1

08/07/2025

SkyX Platforms Corp $SKYX Announces Corporate Update Call Including New Developments Company to Provide Corporate Updates Including New Developments, Second Quarter 2025 Overview and Financial Results; Conference Call to be Held Tuesday, August 12, 2025, at 10:00 A.M. Eastern Time

SKYX Announces Corporate Update Call Including New Developments Company to Provide Corporate Updates Including New Developments, Second Quarter 2025 Overview and Financial Results; Conference Call to be Held Tuesday, August 12, 2025, at 10:00 A.M. Eastern Time

08/07/2025

EDGEMODE Signs Non-Binding Term Sheet for $4 Million Convertible Note to Support Infrastructure Development and Growth Strategy

EdgeMode Signs Non-Binding Term Sheet for $4 Million Convertible Note to Support Infrastructure Development and Growth Strategy

08/07/2025

NextNRG Reports Preliminary July 2025 Revenue Growth of 236% Year-Over-Year

NextNRG Reports Preliminary July 2025 Revenue Growth of 236% Year-Over-Year

08/07/2025

Quoin Pharmaceuticals Announces Second Quarter 2025 Financial Results and Corporate Update

Quoin Pharmaceuticals Announces Second Quarter 2025 Financial Results and Corporate Update

08/06/2025

MetaVia $MTVA Extends 48 mg MAD Portion of Its Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity to 8 Weeks and Announces Fifth Weekly Dose in First Patient

MetaVia Extends 48 mg MAD Portion of Its Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity to 8 Weeks and Announces Fifth Weekly Dose in First Patient